Angion Biomedica Corp:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Angion Biomedica Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3031
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Angion Biomedica Corp (Angion) is a clinical-stage organ restoration biopharmaceutical company that discovers and develops novel treatments for the treatment of renal and chronic organ injury and disease. The company’s pipeline products include BB3, ANG-3070, ANG-3586, ANG-4201, TBD and ANG-4102. Its BB3 is a HGF-like small molecule compound, which is used to treat various indications such as acute kidney injury, renal transplantation and delayed graft function. Angion’s ANG-3070, is a fibrokinase inhibitor which is being developed to treat chronic renal disease. It also conducts preclinical development programs in chronic kidney disease including diabetic nephropathy and polycystic kidney disease. The company operates through its research and development facility located in New York. Angion is headquartered in Uniondale, New York, the US.

Angion Biomedica Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Angion Biomedica Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Angion Biomedica Enters into Licensing Agreement with ElexoPharm 10
Angion Biomedica Enters into Licensing Agreement with Ohr Cosmetics for ANG-3522 11
Equity Offering 12
Angion Biomedica Withdraws IPO 12
Angion Biomedica Corp – Key Competitors 14
Angion Biomedica Corp – Key Employees 15
Angion Biomedica Corp – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Corporate Communications 17
Sep 07, 2017: Angion Biomedica Expands Personnel with New Director of Discovery and Medicinal Chemistry, and Director of Clinical Operations 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Key Facts 2
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Angion Biomedica Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Angion Biomedica Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Angion Biomedica Enters into Licensing Agreement with ElexoPharm 10
Angion Biomedica Enters into Licensing Agreement with Ohr Cosmetics for ANG-3522 11
Angion Biomedica Withdraws IPO 12
Angion Biomedica Corp, Key Competitors 14
Angion Biomedica Corp, Key Employees 15

List of Figures
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Angion Biomedica Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Angion Biomedica Corp:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CBRE Group, Inc.:企業の戦略・SWOT・財務分析
    CBRE Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary CBRE Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Biolase Inc (BIOL):企業の財務・戦略的SWOT分析
    Biolase Inc (BIOL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Laboratory Corp of America Holdings (LH):医療機器:M&Aディール及び事業提携情報
    Summary Laboratory Corp of America Holdings (LabCorp) is a provider of clinical laboratory services and end-to-end drug development support. It focuses on the development and commercialization of a wide range of diagnostic technologies and testing services. The company offers clinical diagnostics la …
  • Baxter International Inc.:企業の戦略・SWOT・財務情報
    Baxter International Inc. - Strategy, SWOT and Corporate Finance Report Summary Baxter International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • General Electric Co (GE):電力:M&Aディール及び事業提携情報
    Summary General Electric Company (GE) is a digital industrial company. It offers a range of industrial, infrastructure and financial services globally. The company offers a range of products and services ranging from aircraft engines, power generation and oil and gas production equipment to medical …
  • Sigmatech, Inc.:企業の戦略・SWOT・財務情報
    Sigmatech, Inc. - Strategy, SWOT and Corporate Finance Report Summary Sigmatech, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Indian Bank:戦略・SWOT・企業財務分析
    Indian Bank - Strategy, SWOT and Corporate Finance Report Summary Indian Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Richard Wolf GmbH:企業の戦略的SWOT分析
    Richard Wolf GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • National Research Corp (NRCIB):企業の財務・戦略的SWOT分析
    Summary National Research Corp (NRC) is a healthcare organization that provides market insight solutions. The company’s solutions include experience collection, market insights, transparency of experience data and governance. It offers market insights solutions that allow the tracking of awareness, …
  • Big Lots, Inc.:企業の戦略・SWOT・財務情報
    Big Lots, Inc. - Strategy, SWOT and Corporate Finance Report Summary Big Lots, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Advicenne SA (ADVIC):製薬・医療:M&Aディール及び事業提携情報
    Summary Advicenne SA (Advicenne) is a developer of pediatric medicines. The company offers product portfolio such as ADV6209, a liquid formulation of a benzodiazepine for moderate sedation and anesthetic premedication; ADV7103, a formulation in the form of micro-tablets for renal tubulopathies. It p …
  • Prezzo Ltd:企業の戦略・SWOT・財務情報
    Prezzo Ltd - Strategy, SWOT and Corporate Finance Report Summary Prezzo Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Staples Inc:企業の戦略的SWOT分析
    Staples Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Syros Pharmaceuticals Inc (SYRS):医療機器:M&Aディール及び事業提携情報
    Summary Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company’s pipeline products under clinical trials include SY-1425, an oral, potent and selective RARa agonist that is used t …
  • The Interpublic Group of Companies, Inc. (IPG):企業の財務・戦略的SWOT分析
    The Interpublic Group of Companies, Inc. (IPG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • BayWa AG:企業のM&A・事業提携・投資動向
    BayWa AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BayWa AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Ontario Power Generation Inc-エネルギー分野:企業M&A・提携分析
    Summary Ontario Power Generation Inc. (OPG) is an electricity generating company, fully owned by the Government of Ontario. It carries out the generation and sale of electricity in Ontario. The company generates electricity by utilizing various sources of energy including nuclear, hydroelectric, bio …
  • iX Biopharma Ltd (42C):企業の財務・戦略的SWOT分析
    Summary iX Biopharma Ltd (iX Biopharma) is a pharmaceutical company that provides that offers drug delivery and formulation. The company's pipeline product portfolio includes development of drugs for various indications such as opioid-sparing for acute, severe and chronic pain; male erectile dysfunc …
  • OJSC Rosneft Oil Company:企業の戦略・SWOT・財務情報
    OJSC Rosneft Oil Company - Strategy, SWOT and Corporate Finance Report Summary OJSC Rosneft Oil Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • VWR International LLC:医療機器:M&Aディール及び事業提携情報
    Summary VWR International LLC (VWR), a subsidiary of Avantor Performance Materials Inc, is a provider of product and service solutions to laboratory and production companies. The company offers products such as adhesive dispensers, adhesive labels, adhesive slides, agarose and acrylamide, air freshe …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆